Europe is watching the latest Ebola outbreak in the Democratic Republic of Congo with a mix of concern and composure. The Bundibugyo strain now circulating in eastern DRC and parts of Uganda has been declared a Public Health Emergency of International Concern, with more than 700 suspected cases and a rising death toll. Yet the risk to people in the EU remains very low, according to the European Centre for Disease Prevention and Control, largely because Ebola requires direct contact with bodily fluids and because Europe’s surveillance and containment systems have strengthened significantly since COVID‑19.
The Bundibugyo strain presents a particular challenge: unlike the Zaire strain behind previous major outbreaks, there are no licensed vaccines or treatments for this variant. A vaccine exists for Zaire Ebola — Ervebo, authorised in the EU in 2019 — but it cannot be deployed here, serving only as a scientific reference point for new candidates. The European Medicines Agency, the World Health Organisation and other EU regulators are now reviewing potential vaccine prototypes, though access to samples from conflict‑affected regions of DRC is slowing research.
Europe’s health authorities are moving quickly but calmly. The Commission has activated the Health Security Committee, issued coordinated guidance on screening and preparedness, and deployed experts to support the Africa Centre for Disease Control and Prevention. An American national infected in DRC has already been transferred to Germany for treatment — a reminder that imported cases are possible, though secondary transmission in Europe remains unlikely. We hope.
The political lesson from COVID‑19 is shaping the response. EU officials emphasise the need to compress vaccine development timelines to 100 days, mirroring the CEPI model created after the 2015 West Africa outbreak. The EU has pledged €74 million to the Coalition for Epidemic Preparedness Innovations to accelerate work on “Disease X” threats, including Ebola variants. But the familiar ‘valley of death’ between research and market‑ready vaccines persists, with industry still reluctant to invest in products for unpredictable outbreaks.
For now, Europe’s posture is one of vigilance without alarm. The systems built during COVID‑19 — rapid sequencing, cross‑border coordination, emergency procurement, and public‑health communication — are being tested again, but from a far stronger starting point. The DRC outbreak is a reminder that global health crises rarely stay neatly contained, yet also that preparedness matters. If COVID‑19 has taught Europe anything, it is that early action, transparent communication, and investment in vaccines are not luxuries but necessities.
